Drugs / 99mTc-PSMA-I&S
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04857502 | Apr 2021 → Jun 2027 expected | prostate carcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04832958 | May 2021 → Nov 2024 | prostate cancer | IRCCS San Raffaele | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-PSMA-I&S | “99mTc-PSMA-I&S will be intravenously injected the day before surgery (day -1).” NCT04832958 ↗1“Diagnostic (99mTc-PSMA-I&S, SPECT/CT)” NCT04857502 ↗ |
| Modality | Diagnostic / imaging agent | “99mTc-PSMA-I&S SPECT/CT imaging” NCT04832958 ↗ |
| Route | Intravenous | “99mTc-PSMA-I&S will be intravenously injected the day before surgery (day -1).” NCT04832958 ↗ |